Resources & News
Resources & News: NSF & Gadolinium
Important Drug Warning for Gadolinium-Based Contrast Agents
MedWatch – 2006 Safety Information Alerts
Information on Gadolinium-Containing Contrast Agents
The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI).
- Information for Healthcare Professionals
- Questions and Answers
Gadolinium-Containing Contrast Agents: Labeling and Regulatory History from Drugs@FDA
- Gadobenate Dimeglumine (marketed as MultiHance)
- Gadodiamide (marketed as Omniscan)
- Gadopentetate Dimeglumine (marketed as Magnevist)
- Gadoteridol (marketed as ProHance)
- Gadoversetamide (marketed as OptiMARK)
Hisorical Information on Gadolinium